Havana, Jul 19 (Prensa Latina) In the midst of an adverse epidemiological situation associated with Covid-19, Cuban government and health authorities continue today the vaccination route designed to protect people with the country’s own products in 2021.
Havana, which just a month ago was the epicenter of the disease, will complete immunization in the coming days in its 15 municipalities with the Abdala injectable, the first vaccine developed in Latin America against Covid-19, which showed 92.28 percent efficacy in clinical trials.
Since the end of May and with a turbulent outlook due to the increase of SARS-Cov-2 virus infections, the Ministry of Public Health decided to implement a health intervention in the capital, other territories and risk groups with two of the vaccine candidates created in the country, due to their positive results in terms of safety and immunogenicity.
The goal is for 60 percent of Cubans to receive their three doses of anti-Covid-19 injectables by August and to continue in September with children under 18 years of age, a population group with a high incidence of positive results.
Hence, clinical trials aimed at children and adolescents are now being added to the strategy: Pediatric Soberana, which is being applied in Havana with the vaccine candidate Soberana 02 and Soberana Plus, from the Finlay Vaccine Institute, which achieved 91.2 percent efficacy with two doses of the former and a third dose of the latter.
Also with Abdala, from the Center for Genetic Engineering and Biotechnology, another research is being carried out in that age group in the eastern province of Camagüey, a territory hit by the pandemic in recent times.
For 10 consecutive days, the number of infections in the country has exceeded 6,000 per day due to a marked autochthonous transmission of the SARS-Cov-2 virus, while the western province of Matanzas is the epicenter of the disease with reports of around 2,000 cases in a single day.
To date, according to official data, 8,146,748 doses of both anti-Covid-19 products have been administered, and 2,91,439 people have received the three injections, to complete the immunization scheme designed in this country against the virus.
(Taken from PL)